PELLICANO, CLELIA
 Distribuzione geografica
Continente #
NA - Nord America 1.610
EU - Europa 275
AS - Asia 196
SA - Sud America 9
AF - Africa 6
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 2.098
Nazione #
US - Stati Uniti d'America 1.604
IT - Italia 86
SE - Svezia 59
IN - India 55
CN - Cina 52
SG - Singapore 47
FI - Finlandia 31
UA - Ucraina 31
IL - Israele 29
DE - Germania 17
BG - Bulgaria 11
BE - Belgio 10
GB - Regno Unito 9
AR - Argentina 8
CA - Canada 6
IE - Irlanda 6
RO - Romania 6
TG - Togo 6
ES - Italia 3
IR - Iran 3
NL - Olanda 3
TR - Turchia 3
HK - Hong Kong 2
AU - Australia 1
CH - Svizzera 1
CO - Colombia 1
EU - Europa 1
FR - Francia 1
JO - Giordania 1
JP - Giappone 1
MY - Malesia 1
RU - Federazione Russa 1
TW - Taiwan 1
VN - Vietnam 1
Totale 2.098
Città #
Fairfield 271
Ashburn 139
Chandler 134
Seattle 127
Woodbridge 125
Cambridge 104
Houston 104
Wilmington 79
Ann Arbor 59
Princeton 36
Plano 32
Rome 32
Singapore 32
Beijing 27
Dearborn 25
Millbury 24
Lawrence 22
San Diego 19
Jacksonville 17
San Paolo di Civitate 16
Boston 15
Norwalk 13
Sofia 11
Brussels 10
New York 10
Andover 8
Des Moines 8
Federal 8
Boardman 6
Cagliari 6
Fremont 6
Helsinki 6
Kunming 6
Lomé 6
Toronto 6
Dublin 5
Falls Church 4
Hefei 4
Mannheim 4
Phoenix 4
Redwood City 4
Buffalo 3
Istanbul 3
Nanchang 3
Philadelphia 3
Terrassa 3
Amsterdam 2
Bonndorf 2
Bühl 2
Falkenstein 2
Galdo 2
Indiana 2
Jinan 2
Los Angeles 2
Nanjing 2
Osio Sotto 2
Redmond 2
Salerno 2
Southend 2
Zanjan 2
Alatri 1
Amman 1
Bogotá 1
Brescia 1
Cesana 1
Chengdu 1
Cluj-napoca 1
Coominya 1
Florence 1
Frankfurt am Main 1
Guangzhou 1
Gunzenhausen 1
Hanoi 1
Laurel 1
Lausanne 1
Leawood 1
Les Arcs 1
Lessolo 1
London 1
Milan 1
Modena 1
Nishikicho 1
Nürnberg 1
Pomezia 1
Provo 1
Pune 1
San Francisco 1
San Genesio Ed Uniti 1
San Mateo 1
Santa Clara 1
Scafati 1
Shaoxing 1
Shenyang 1
Springfield 1
Taipei 1
Zhengzhou 1
Totale 1.653
Nome #
Acceptability to patients, carers and clinicians of an mHealth platform for the management of Parkinson's disease (PD_Manager): study protocol for a pilot randomised controlled trial 100
Phosphorylated α-synuclein immunoreactivity in nerve fibers from minor salivary glands in Parkinson's disease 99
Minocycline in amyotrophic lateral sclerosis: a pilot study 97
Prodromal non-motor symptoms of Parkinson's disease 90
Intensity-dependent facial emotion recognition and cognitive functions in Parkinson's disease. 87
Tako tsubo and ischemic stroke in a patient with Alzheimer’s disease 82
Psychiatric profile of motor subtypes of de novo drug-naïve Parkinson's disease patients 82
Neuropsychiatric and cognitive symptoms and body side of onset of parkinsonism in unmedicated Parkinson's disease patients 79
Alpha-synuclein in salivary gland as biomarker for Parkinson's disease 79
The Dopaminergic System in Peripheral Blood Lymphocytes: From Physiology to Pharmacology and Potential Applications to Neuropsychiatric Disorders 78
Bupropion abates dopamine agonist-mediated compulsive behaviors in Parkinson's disease. 78
The impact of extended release dopamine agonists on prescribing patterns for therapy of early Parkinson’s disease: an observational study. 76
Entacapone in elderly Parkinsonian patients experiencing levodopa-related wearing-off: a pilot study 74
Dopamine transporter immunoreactivity in peripheral blood lymphocytes discriminates Parkinson's disease from essential tremor 72
Relationship of cortical atrophy to fatigue in patients with multiple sclerosis 68
Dopamine transporter immunoreactivity in peripheral blood lymphocytes in multiple system atrophy 66
Dopamine transporter immunoreactivity in peripheral blood mononuclear cells in amyotrophic lateral sclerosis 63
Characterizing contrast-enhancing and re-enhancing lesions in multiple sclerosis 62
T1 cortical hypointensities and their association with cognitive disability in multiple sclerosis 61
Quality and Quantity of Diffuse and Focal White Matter Disease and Cognitive Disability of Patients with Multiple Sclerosis 61
null 59
Central and peripheral dopamine transporter reduction in Parkinson's disease 57
Neuropsychiatric and cognitive symptoms in Parkinson’s disease: the contribution to subtype classification, to differential diagnosis, their clinical and instrumental correlations 55
null 54
null 50
Regional cortical thickness and cognitive functions in non-demented Parkinson's disease patients: a pilot study 50
null 47
Neuropharmacology and behavior in planaria: translations to mammals 45
Hemiparkinsonism due to frontal meningioma 41
null 41
null 25
Neuropsychiatric and cognitive profile of early Richardson's syndrome, Progressive Supranuclear Palsy-parkinsonism and Parkinson's disease 18
Unraveling predictors affecting compliance to MRI inParkinson'sdisease 14
Morphometric changes in the reward system of Parkinson’s disease patients with impulse control disorders 14
null 13
Levodopa/Carbidopa Intestinal Gel for Treatment of Advanced Parkinson’s Disease: An Update on the Effects of Cognitive Functions 13
On the relationship between side of onset and cognition in Parkinson disease: Response from the authors 11
Neuropsychiatric, neuropsychological, and neuroimaging features in isolated REM sleep behavior disorder: The importance of MCI 6
null 4
Staging and clinical correlates of cortical thinning in Parkinson’s disease 2
Totale 2.173
Categoria #
all - tutte 5.549
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.549


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020526 0 0 0 29 66 82 94 71 77 40 25 42
2020/2021151 16 20 24 6 8 11 3 14 22 18 8 1
2021/2022338 4 23 32 6 39 13 11 34 22 24 61 69
2022/2023386 70 70 33 40 41 45 0 24 50 2 8 3
2023/2024153 12 26 2 13 9 23 4 19 1 12 16 16
2024/202556 11 11 33 1 0 0 0 0 0 0 0 0
Totale 2.173